Ginsenoside RcCAS# 11021-14-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 11021-14-0 | SDF | Download SDF |
PubChem ID | 100018 | Appearance | White powder |
Formula | C53H90O22 | M.Wt | 1079.27 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Synonyms | Panaxoside Rc | ||
Solubility | H2O : 50 mg/mL (46.33 mM; Need ultrasonic) | ||
Chemical Name | 2-[2-[[17-[2-[6-[[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | ||
SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(O8)CO)O)O)O)O)O)C | ||
Standard InChIKey | JDCPEKQWFDWQLI-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Ginsenoside Rc exhibits anti-diabetic, anti-adipogenic, anticancer and anti-inflammatory activities; it can attenuate inflammatory symptoms of gastritis, hepatitis and arthritis, and it can significantly enhance glucose uptake by inducing ROS generation, which leads to AMPK and p38 MAPK activation. Rc enhances GABA receptorA (GABAA)-mediated ion channel currents (IGABA), it also inhibits the expression of TNF-α and IL-1β. |
Targets | PPAR | AP-1 | PI3K | Akt | AMPK | PKB | p38MAPK | ROS | IL Receptor | cAMP | TNF-α | NF-kB | GABA receptor |
In vitro | Ginsenoside Rc promotes anti-adipogenic activity on 3T3-L1 adipocytes by down-regulating C/EBPα and PPARγ.[Pubmed: 25594343]Molecules. 2015 Jan 14;20(1):1293-303.Panax ginseng and its major components, the ginsenosides, are widely used in oriental medicine for the prevention of various disorders.
Ginsenoside Rc and Re stimulate c-fos expression in MCF-7 human breast carcinoma cells.[Pubmed: 12568359]Arch Pharm Res. 2003 Jan;26(1):53-7.We have found that Ginsenoside Rc and Re induce c-fos in MCF-7 human breast carcinoma cells at both the mRNA and protein levels. However, neither ginsenoside activated the expression of reporter gene under the control of AP-1/TPA response elements.
|
In vivo | Ginsenoside Rc from Korean Red Ginseng (Panax ginseng C.A. Meyer) Attenuates Inflammatory Symptoms of Gastritis, Hepatitis and Arthritis.[Pubmed: 27109153 ]Am J Chin Med. 2016;44(3):595-615.Korean Red Ginseng (KRG) is an herbal medicine prescribed worldwide that is prepared from Panax ginseng C.A. Meyer (Araliaceae). Out of ginseng's various components, ginsenosides are regarded as the major ingredients, exhibiting anticancer and anti-inflammatory activities. Although recent studies have focused on understanding the anti-inflammatory activities of KRG, compounds that are major anti-inflammatory components, precisely how these can suppress various inflammatory processes has not been fully elucidated yet.
In this study, we aimed to identify inhibitory saponins, to evaluate the in vivo efficacy of the saponins, and to understand the inhibitory mechanisms. |
Kinase Assay | Ginsenoside Rc, an active component of Panax ginseng, stimulates glucose uptake in C2C12 myotubes through an AMPK-dependent mechanism.[Pubmed: 19961916 ]J Ethnopharmacol. 2010 Feb 17;127(3):771-6.Panax ginseng and its major component, ginsenosides, are widely used for the prevention of various disorders in oriental medicine.
To evaluate the effect of Ginsenoside Rc (Rc), one of the active constituents in Panax ginseng, on glucose uptake in C2C12 myotubes.
|
Cell Research | Ginsenoside Rc modulates Akt/FoxO1 pathways and suppresses oxidative stress.[Pubmed: 23918648]Arch Pharm Res. 2014 Jun;37(6):813-20.Ginsenoside Rc (Rc), a protopanaxadiol type ginsenoside, is the active component mainly responsible for the therapeutic and pharmacologic properties of ginseng, which are derived from its suppression of superoxide-induced free radicals. Forkhead box O (FoxO1) regulates various genes involved in cellular metabolism related to cell death and response to oxidative stress, and Rc is known to prevent FoxO1 phosphorylation by activation of PI3K/Akt and subsequent inhibition of AMP-activated protein kinase (AMPK) in cells exposed to tert-butylhydroperoxide (t-BHP).
|
Ginsenoside Rc Dilution Calculator
Ginsenoside Rc Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 0.9266 mL | 4.6328 mL | 9.2655 mL | 18.531 mL | 23.1638 mL |
5 mM | 0.1853 mL | 0.9266 mL | 1.8531 mL | 3.7062 mL | 4.6328 mL |
10 mM | 0.0927 mL | 0.4633 mL | 0.9266 mL | 1.8531 mL | 2.3164 mL |
50 mM | 0.0185 mL | 0.0927 mL | 0.1853 mL | 0.3706 mL | 0.4633 mL |
100 mM | 0.0093 mL | 0.0463 mL | 0.0927 mL | 0.1853 mL | 0.2316 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptorA (GABAA)-mediated ion channel currents (IGABA). Ginsenoside Rc inhibits the expression of TNF-α and IL-1β.
In Vitro:Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances γ-aminobutyric acid (GABA) receptorA (GABAA)-mediated ion channel currents. Ginsenoside Rc enhances GABA-mediated ion currents in oocytes expressing the GABAA receptor[1]. Ginsenoside Rc significantly inhibits the expression of macrophage-derived cytokines, such as TNF-α and IL-1β. Ginsenoside Rc also markedly suppresses the activation of TANK-binding kinase 1/IκB kinase ε/interferon regulatory factor-3 and p38/ATF-2 signaling in activated RAW264.7 macrophages, human synovial cells, and HEK293 cells. Ginsenoside Rc exerts its anti-inflammatory actions by suppressing TANK-binding kinase 1/IκB kinase ε/interferon regulatory factor-3 and p38/ATF-2 signaling. Ginsenoside Rc suppresses the nuclear translocation of phospho-ATF-2 and phospho-FRA-1, whereas the translocation of p65 at its peak time points (30 and 60 min) is not decreased by Ginsenoside Rc treatment. Ginsenoside Rc regulates the expression of the proinflammatory cytokine TNF-α, which is produced by macrophages, by suppressing AP-1 activation[2].
References:
[1]. Lee BH, et al. Effects of Ginsenoside Metabolites on GABAA Receptor-Mediated Ion Currents. J Ginseng Res. 2012 Jan;36(1):55-60.
[2]. Yu T, et al. Ginsenoside Rc from Panax ginseng exerts anti-inflammatory activity by targeting TANK-bindingkinase 1/interferon regulatory factor-3 and p38/ATF-2. J Ginseng Res. 2017 Apr;41(2):127-133.
- Ginsenoside Rb2
Catalog No.:BCN1064
CAS No.:11021-13-9
- Cochliophilin A
Catalog No.:BCC8154
CAS No.:110204-45-0
- Malonylginsenoside Rb(1)
Catalog No.:BCC9230
CAS No.:88140-34-5
- 1,5,8-Trihydroxy-3-methoxy-2-prenylxanthone
Catalog No.:BCN1623
CAS No.:110187-11-6
- JZL184
Catalog No.:BCC4790
CAS No.:1101854-58-3
- Ouabain Octahydrate
Catalog No.:BCC5211
CAS No.:11018-89-6
- 4-Galloylquinic acid
Catalog No.:BCN3733
CAS No.:110170-37-1
- Methyl hesperidin
Catalog No.:BCN6341
CAS No.:11013-97-1
- Indoximod (NLG-8189)
Catalog No.:BCC5584
CAS No.:110117-83-4
- Ascomycin
Catalog No.:BCN8286
CAS No.:11011-38-4
- des-His1-[Glu9]-Glucagon (1-29) amide
Catalog No.:BCC5885
CAS No.:110084-95-2
- Plerixafor (AMD3100)
Catalog No.:BCC1158
CAS No.:110078-46-1
- Temocapril HCl
Catalog No.:BCC5016
CAS No.:110221-44-8
- Nothofagin
Catalog No.:BCN3787
CAS No.:11023-94-2
- Digitonin
Catalog No.:BCN3734
CAS No.:11024-24-1
- (-)-beta-Peltatin-5-O-beta-D-glucopyranoside
Catalog No.:BCN3607
CAS No.:11024-59-2
- Ganoderic acid N
Catalog No.:BCN2438
CAS No.:110241-19-5
- Ganoderenic acid E
Catalog No.:BCN8241
CAS No.:110241-23-1
- Amrubicin
Catalog No.:BCC3640
CAS No.:110267-81-7
- Agnuside
Catalog No.:BCN5990
CAS No.:11027-63-7
- Bacoside A
Catalog No.:BCC8127
CAS No.:11028-00-5
- CI 966 hydrochloride
Catalog No.:BCC7010
CAS No.:110283-66-4
- Santalol
Catalog No.:BCN8352
CAS No.:11031-45-1
- α-Bungarotoxin
Catalog No.:BCC7264
CAS No.:11032-79-4
Ginsenoside Rc, an active component of Panax ginseng, stimulates glucose uptake in C2C12 myotubes through an AMPK-dependent mechanism.[Pubmed:19961916]
J Ethnopharmacol. 2010 Feb 17;127(3):771-6.
ETHNOPHARMACOLOGICAL RELEVANCE: Panax ginseng and its major component, ginsenosides, are widely used for the prevention of various disorders in oriental medicine. AIM OF THE STUDY: To evaluate the effect of Ginsenoside Rc (Rc), one of the active constituents in Panax ginseng, on glucose uptake in C2C12 myotubes. RESULTS: Treatment of the C2C12 myotubes with Rc significantly increased glucose uptake. To determine the mechanism of Rc-induced glucose uptake, either insulin-dependent signaling or insulin-independent signaling pathway activities were measured using western blot analysis. We showed that Rc significantly activated an insulin-independent AMPK signaling pathway. However, Rc had no effect on the components of the insulin-dependent signaling pathway, such as receptor substrates (IRS)-1 and protein kinase B or Akt (PKB/Akt). Moreover, we found that treatment with an AMPK inhibitor abolished both glucose uptake and p38 MAPK phosphorylation. This result implies that AMPK activity is critical for the Rc-induced glucose uptake and that AMPK is situated upstream of p38 MAPK. In addition, we also showed that the activation of AMPK and p38 induced by Ginsenoside Rc is mediated by reactive oxygen species (ROS) production, suggesting that upstream regulators of AMPK- and p38 MAPK-mediated glucose uptake. CONCLUSION: Ginsenoside Rc significantly enhances glucose uptake by inducing ROS generation, which leads to AMPK and p38 MAPK activation. Consequently, Ginsenoside Rc can be used as a potent natural anti-diabetic agent.
Ginsenoside Rc promotes anti-adipogenic activity on 3T3-L1 adipocytes by down-regulating C/EBPalpha and PPARgamma.[Pubmed:25594343]
Molecules. 2015 Jan 14;20(1):1293-303.
Panax ginseng and its major components, the ginsenosides, are widely used in oriental medicine for the prevention of various disorders. In the present study, the inhibitory activity of Ginsenoside Rc on adipogenesis was investigated using the 3T3-L1 cell line. The results obtained showed that Rc reduced the proliferation and viability of 3T3-L1 preadipocytes in a dose-dependent manner. Treatment with Rc decreased the number of adipocytes and reduced lipid accumulation in maturing 3T3-L1 preadipocytes, demonstrating an inhibitory effect on lipogenesis. Moreover, it was found that Rc directly induced lipolysis in adipocytes and down-regulated the expression of major transcription factors of the adipogenesis pathway, such as PPARgamma and C/EBPalpha. These findings indicate that Rc is capable of suppressing adipogenesis and therefore they seem to be natural bioactive factors effective in adipose tissue mass modulation.
Ginsenoside Rc and Re stimulate c-fos expression in MCF-7 human breast carcinoma cells.[Pubmed:12568359]
Arch Pharm Res. 2003 Jan;26(1):53-7.
We have found that Ginsenoside Rc and Re induce c-fos in MCF-7 human breast carcinoma cells at both the mRNA and protein levels. However, neither ginsenoside activated the expression of reporter gene under the control of AP-1/TPA response elements. We have also examined the possibility that Ginsenoside Rc and Re act by binding to intracellular steroid hormone receptors that act as transcriptional factors in the nucleus in inducing c-fos mRNA in MCF7 human breast carcinoma cells. However, Ginsenoside Rc and Re did not bind to glucocorticoid, androgen, estrogen, or retinoic acid receptors as examined by the transcription activation of the luciferase reporter genes in CV-1 cells that were transiently transfected with the corresponding steroid hormone receptors and hormone responsive luciferase reporter plasmids. These data demonstrate that Ginsenoside Rc and Re act via other transcription factors and not via estrogen receptor in c-Fos expression.
Ginsenoside Rc modulates Akt/FoxO1 pathways and suppresses oxidative stress.[Pubmed:23918648]
Arch Pharm Res. 2014 Jun;37(6):813-20.
Ginsenoside Rc (Rc), a protopanaxadiol type ginsenoside, is the active component mainly responsible for the therapeutic and pharmacologic properties of ginseng, which are derived from its suppression of superoxide-induced free radicals. Forkhead box O (FoxO1) regulates various genes involved in cellular metabolism related to cell death and response to oxidative stress, and Rc is known to prevent FoxO1 phosphorylation by activation of PI3K/Akt and subsequent inhibition of AMP-activated protein kinase (AMPK) in cells exposed to tert-butylhydroperoxide (t-BHP). In the current study, we attempted the mechanism of increased catalase expression by Rc through inhibition of FoxO1 activation resulting from t-BHP-induced production of reactive species (RS). We found that overexpression of catalase induced by Rc resulted in suppression of RS production in kidney human embryo kidney 293T cells (HEK293T) cells, and that oxidative stress induced activation of PI3K/Akt and inhibition of the AMPK pathway and FoxO1 phosphorylation, leading to down-regulation of catalase, a FoxO1-targeting gene. In addition, treatment of HEK293T cells with Rc resulted in cAMP-response element-binding protein (CREB)-binding protein (CBP) regulated FoxO1 acetylation. Our results suggest that Rc modulates FoxO1 phosphorylation through activation of PI3K/Akt and inhibition of AMPK and FoxO1 acetylation through interaction with CBP and SIRT1, and that this leads to upregulation of catalase under conditions of oxidative stress.
Ginsenoside Rc from Korean Red Ginseng (Panax ginseng C.A. Meyer) Attenuates Inflammatory Symptoms of Gastritis, Hepatitis and Arthritis.[Pubmed:27109153]
Am J Chin Med. 2016;44(3):595-615.
Korean Red Ginseng (KRG) is an herbal medicine prescribed worldwide that is prepared from Panax ginseng C.A. Meyer (Araliaceae). Out of ginseng's various components, ginsenosides are regarded as the major ingredients, exhibiting anticancer and anti-inflammatory activities. Although recent studies have focused on understanding the anti-inflammatory activities of KRG, compounds that are major anti-inflammatory components, precisely how these can suppress various inflammatory processes has not been fully elucidated yet. In this study, we aimed to identify inhibitory saponins, to evaluate the in vivo efficacy of the saponins, and to understand the inhibitory mechanisms. To do this, we employed in vitro lipopolysaccharide-treated macrophages and in vivo inflammatory mouse conditions, such as collagen (type II)-induced arthritis (CIA), EtOH/HCl-induced gastritis, and lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-triggered hepatitis. Molecular mechanisms were also verified by real-time PCR, immunoblotting analysis, and reporter gene assays. Out of all the ginsenosides, Ginsenoside Rc (G-Rc) showed the highest inhibitory activity against the expression of tumor necrosis factor (TNF)-[Formula: see text], interleukin (IL)-1[Formula: see text], and interferons (IFNs). Similarly, this compound attenuated inflammatory symptoms in CIA, EtOH/HCl-mediated gastritis, and LPS/D-galactosamine (D-GalN)-triggered hepatitis without altering toxicological parameters, and without inducing gastric irritation. These anti-inflammatory effects were accompanied by the suppression of TNF-[Formula: see text] and IL-6 production and the induction of anti-inflammatory cytokine IL-10 in mice with CIA. G-Rc also attenuated the increased levels of luciferase activity by IRF-3 and AP-1 but not NF-[Formula: see text]B. In support of this phenomenon, G-Rc reduced TBK1, IRF-3, and ATF2 phosphorylation in the joint and liver tissues of mice with hepatitis. Therefore, our results strongly suggest that G-Rc may be a major component of KRG with useful anti-inflammatory properties due to its suppression of IRF-3 and AP-1 pathways.